AC Immune(US:ACIU)2025-12-11 14:00Company Overview - AC Immune is focused on precision prevention of neurodegenerative diseases, particularly Alzheimer's and Parkinson's [4] - The company has potential partnering milestones exceeding CHF 4.3 billion [4] - As of September 30, 2025, AC Immune's cash reserves were CHF 108.5 million [6], equivalent to approximately USD 136 million [4] - The company has 100.9 million shares outstanding [6] ACI-7104 Phase 2 Interim Results - The Phase 2 study of ACI-7104 included a total enrollment of 34 patients [24] - The most common adverse events (AEs) were injection site reactions (55.9%), headaches (14.7%), and fatigue (11.8%) [28] - ACI-7104 demonstrated a 100% responder rate for anti-PD012 antibody titers in serum [29] - ACI-7104 treatment showed a trend towards stabilization of disease progression, with the MDS-UPDRS Part III total score suggesting stabilization [67] Biomarker and Imaging Findings - ACI-7104 immunization stabilized total alpha-synuclein levels in cerebrospinal fluid (CSF), demonstrating target engagement [41] - Neurofilament light chain (NfL) levels in CSF remained stable in the ACI-7104 group, suggesting a potential slowing of neurodegeneration [43] - Dopamine transporter (DaT-SPECT) imaging suggested stabilization of Parkinson's disease pathology [50]